Vertex Pharmaceuticals Stock Price, News & Analysis (NASDAQ:VRTX)

$157.97 0.78 (0.50 %)
(As of 01/21/2018 04:00 PM ET)
Previous Close$157.97
Today's Range$156.32 - $159.50
52-Week Range$80.06 - $167.85
Volume2.09 million shs
Average Volume1.50 million shs
Market Capitalization$39.95 billion
P/E Ratio202.53
Dividend YieldN/A

About Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals logoVertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Receive VRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs


Debt-to-Equity Ratio0.01%
Current Ratio3.28%
Quick Ratio3.14%


Trailing P/E Ratio202.525641025641
Forward P/E Ratio205.16
P/E Growth1.87

Sales & Book Value

Annual Sales$1.70 billion
Price / Sales23.47
Cash Flow$0.14 per share
Price / Cash1,124.50
Book Value$5.39 per share
Price / Book29.31


Trailing EPS$0.78
Net Income$-112,050,000.00
Net Margins8.53%
Return on Equity9.23%
Return on Assets5.01%


Outstanding Shares252,900,000

Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted its quarterly earnings data on Wednesday, October, 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.49. The pharmaceutical company had revenue of $578.20 million for the quarter, compared to analysts' expectations of $522.07 million. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The company's quarterly revenue was up 39.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.16 EPS. View Vertex Pharmaceuticals' Earnings History.

When will Vertex Pharmaceuticals make its next earnings announcement?

Vertex Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, January, 31st 2018. View Earnings Estimates for Vertex Pharmaceuticals.

Where is Vertex Pharmaceuticals' stock going? Where will Vertex Pharmaceuticals' stock price be in 2018?

26 Wall Street analysts have issued 12-month price objectives for Vertex Pharmaceuticals' shares. Their predictions range from $85.00 to $205.00. On average, they expect Vertex Pharmaceuticals' stock price to reach $175.75 in the next year. View Analyst Ratings for Vertex Pharmaceuticals.

What are Wall Street analysts saying about Vertex Pharmaceuticals stock?

Here are some recent quotes from research analysts about Vertex Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Vertex has two CF drugs — Kalydeco & Orkambi — in its portfolio with blockbuster potential. For Vertex, 2017 was a tremendous year with positive data read-outs and regulatory approvals leading to an increase in the eligible patient population for Kalydeco & Orkambi. Vertex’s CF pipeline is also quite strong with a broad portfolio of next-generation CF correctors. Investor focus is on the triple combination CF regimens, which are crucial for long-term growth, as they have the potential to treat up to 90% of CF patients. The stock shot up in the past one year. Estimates have slightly gone up ahead of Q4 earnings release. The company has a positive record of earnings surprises in the recent quarters. However, Vertex has faced some challenges with respect to commercialization of Orkambi in ex-U.S. markets due to re-imbursement hurdles. Orkambi’s reimbursement in France remains a key for sales growth in 2018." (1/21/2018)
  • 2. Maxim Group analysts commented, "The Winter Olympics are coming this February and what do the judges want to see? A triple…Will Vertex score a perfect 10? We’ll see as two triples go pivotal and more P2 2 data, which has already impressed, comes in early 2018." (10/26/2017)
  • 3. Cowen Inc analysts commented, "Vertex announced that the FDA has approved Kalydeco for use in CF patients over the." (8/1/2017)
  • 4. Needham & Company LLC analysts commented, "Vertex announced 1Q17 financial results last night. Orkambi WW sales $295M beat our $277.5M and consensus $280M ests. Kalydeco WW sales $186M beat our $178.0M and consensus $175M ests. Mgmt raised Kalydeco, but left unch Orkambi guidance ($1.1-1.3B Orkambi and $710M-$730M from $690-710M Kalydeco). Orkambi driven by strong uptake and compliance in pediatric pts and Kalydeco driven by one time reimbursement in Europe. Our 2Q17 Orkambi and Kalydeco ests are $294.0M (was $287.5M) and $179.0M (was $178.0M). Stock reflects IVA/ TEZ commercial success and we maintain HOLD." (4/28/2017)

Who are some of Vertex Pharmaceuticals' key competitors?

Who are Vertex Pharmaceuticals' key executives?

Vertex Pharmaceuticals' management team includes the folowing people:

  • Jeffrey M. Leiden M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 61)
  • Thomas Graney, Chief Financial Officer, Senior Vice President (Age 52)
  • Ian F. Smith CPA, Chief Operating Officer, Executive Vice President (Age 51)
  • Michael J. Parini J.D., Executive Vice President, Chief Legal and Administrative Officer (Age 42)
  • David Altshuler M.D., Ph.D., Executive Vice President - Global Research, Chief Scientific Officer (Age 52)
  • Stuart A. Arbuckle, Executive Vice President, Chief Commercial Officer (Age 51)
  • Jeffrey A. Chodakewitz M.D., Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer (Age 61)
  • Amit K. Sachdev J.D., Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO (Age 49)
  • Paul M. Silva, Senior Vice President, Corporate Controller (Age 51)
  • Bruce I. Sachs, Lead Director, Independent Director (Age 57)

Who owns Vertex Pharmaceuticals stock?

Vertex Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.38%), Atalanta Sosnoff Capital LLC (0.19%), Bank of Montreal Can (0.14%), National Pension Service (0.09%), Westpac Banking Corp (0.05%) and Cullinan Associates Inc. (0.04%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Michael Parini, Paul M Silva, Sangeeta N Bhatia, Stuart A Arbuckle and Thomas Graney. View Institutional Ownership Trends for Vertex Pharmaceuticals.

Who sold Vertex Pharmaceuticals stock? Who is selling Vertex Pharmaceuticals stock?

Vertex Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, National Pension Service, Exxonmobil Investment Management Inc. TX, Oakbrook Investments LLC, Livforsakringsbolaget Skandia Omsesidigt, Convergence Investment Partners LLC and Louisiana State Employees Retirement System. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Michael Parini, Paul M Silva, Sangeeta N Bhatia, Stuart A Arbuckle and Thomas Graney. View Insider Buying and Selling for Vertex Pharmaceuticals.

Who bought Vertex Pharmaceuticals stock? Who is buying Vertex Pharmaceuticals stock?

Vertex Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Atalanta Sosnoff Capital LLC, Westpac Banking Corp, Bank of Montreal Can, Schwab Charles Investment Management Inc., State of Alaska Department of Revenue, Nisa Investment Advisors LLC, Fox Run Management L.L.C. and Moody National Bank Trust Division. View Insider Buying and Selling for Vertex Pharmaceuticals.

How do I buy Vertex Pharmaceuticals stock?

Shares of Vertex Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vertex Pharmaceuticals' stock price today?

One share of Vertex Pharmaceuticals stock can currently be purchased for approximately $157.97.

How big of a company is Vertex Pharmaceuticals?

Vertex Pharmaceuticals has a market capitalization of $39.95 billion and generates $1.70 billion in revenue each year. The pharmaceutical company earns $-112,050,000.00 in net income (profit) each year or $0.78 on an earnings per share basis. Vertex Pharmaceuticals employs 2,150 workers across the globe.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 Northern Ave, BOSTON, MA 02210-1862, United States. The pharmaceutical company can be reached via phone at +1-617-3416393 or via email at [email protected]

MarketBeat Community Rating for Vertex Pharmaceuticals (VRTX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,025 (Vote Outperform)
Underperform Votes:  560 (Vote Underperform)
Total Votes:  1,585
MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vertex Pharmaceuticals (NASDAQ:VRTX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.962.922.882.88
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
25 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
24 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
23 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $175.75$172.83$166.16$157.04
Price Target Upside: 12.69% upside22.66% upside7.17% upside3.75% downside

Vertex Pharmaceuticals (NASDAQ:VRTX) Consensus Price Target History

Price Target History for Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals (NASDAQ:VRTX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/9/2018JPMorgan Chase & Co.Reiterated RatingBuyLowView Rating Details
1/5/2018Bank of AmericaUpgradeNeutral -> Buy$180.00LowView Rating Details
1/4/2018OppenheimerBoost Price TargetOutperform$175.00 -> $190.00LowView Rating Details
12/12/2017Deutsche BankInitiated CoverageBuy$175.00HighView Rating Details
12/11/2017CowenReiterated RatingBuy$200.00LowView Rating Details
10/27/2017Royal Bank of CanadaReiterated RatingBuyN/AView Rating Details
10/27/2017Needham & Company LLCReiterated RatingBuy$195.00N/AView Rating Details
10/27/2017Robert W. BairdReiterated RatingBuyN/AView Rating Details
10/26/2017HC WainwrightReiterated RatingHold$85.00N/AView Rating Details
10/26/2017Maxim GroupReiterated RatingBuy$195.00N/AView Rating Details
10/26/2017Piper Jaffray CompaniesReiterated RatingOverweight$205.00N/AView Rating Details
9/29/2017DA DavidsonInitiated CoverageBuy$200.00LowView Rating Details
9/29/2017BTIG ResearchInitiated CoverageBuy -> Buy$200.00MediumView Rating Details
9/27/2017BMO Capital MarketsReiterated RatingBuyLowView Rating Details
8/22/2017Jefferies GroupReiterated RatingBuyHighView Rating Details
8/1/2017ArgusBoost Price TargetBuy$71.46 -> $175.00LowView Rating Details
7/22/2017Morgan StanleyReiterated RatingOverweight$153.00 -> $190.00LowView Rating Details
7/21/2017CitigroupReiterated RatingBuy$135.00 -> $190.00LowView Rating Details
7/19/2017Credit Suisse GroupBoost Price TargetOutperform$125.00 -> $195.00HighView Rating Details
7/19/2017JMP SecuritiesReiterated RatingOutperformHighView Rating Details
7/19/2017Raymond James FinancialUpgradeMarket Perform -> Outperform$181.00HighView Rating Details
7/19/2017Janney Montgomery ScottUpgradeNeutral -> Buy$98.00HighView Rating Details
7/19/2017BarclaysUpgradeEqual Weight -> Overweight$115.00 -> $180.00HighView Rating Details
7/18/2017Stifel NicolausBoost Price TargetBuy -> Buy$130.00 -> $154.00HighView Rating Details
6/22/2017Leerink SwannReiterated RatingOutperformMediumView Rating Details
6/2/2017CIBCUpgradeMarket Perform -> OutperformLowView Rating Details
11/1/2016William BlairDowngradeOutperform -> Market Perform$105.00 -> $81.00N/AView Rating Details
4/28/2016Goldman Sachs GroupDowngradeBuy -> Neutral$109.00 -> $88.00N/AView Rating Details
3/28/2016GuggenheimLower Price TargetBuy$145.00 -> $114.00N/AView Rating Details
(Data available from 1/21/2016 forward)


Vertex Pharmaceuticals (NASDAQ:VRTX) Earnings History and Estimates Chart

Earnings by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals (NASDAQ VRTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/31/2018$0.47N/AView Earnings Details
10/25/2017Q3 2017$0.04$0.53$522.07 million$578.20 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.06$0.39$489.95 million$544.10 millionViewN/AView Earnings Details
4/27/2017Q1 2017$0.04$0.13$692.64 million$714.72 millionViewN/AView Earnings Details
1/25/2017Q4 2016$0.29$0.35$453.40 million$458.71 millionViewN/AView Earnings Details
10/25/2016Q316$0.18$0.16$423.53 million$413.78 millionViewListenView Earnings Details
7/27/2016Q216$0.21$0.24$428.08 million$431.61 millionViewListenView Earnings Details
4/27/2016Q116$0.29$0.09$439.94 million$398.10 millionViewListenView Earnings Details
1/27/2016Q4$0.17$0.17$406.30 million$417.94 millionViewListenView Earnings Details
10/28/2015Q315($0.60)($0.13)$245.84 million$309.82 millionViewListenView Earnings Details
7/29/2015Q215($0.58)($0.54)$149.49 million$166.00 millionViewListenView Earnings Details
4/29/2015Q115($0.75)($0.62)$142.38 million$138.51 millionViewListenView Earnings Details
1/28/2015Q414($0.65)($0.55)$137.50 million$144.56 millionViewListenView Earnings Details
10/28/2014Q314($0.62)($0.37)$146.20 million$179.00 millionViewN/AView Earnings Details
7/29/2014Q214($0.71)($0.61)$131.85 million$138.42 millionViewListenView Earnings Details
5/1/2014Q114($0.68)($0.65)$134.46 million$118.50 millionViewN/AView Earnings Details
1/29/2014Q413($0.49)($0.56)$221.08 million$351.20 millionViewListenView Earnings Details
10/29/2013Q413($0.33)($0.32)$278.80 million$222.00 millionViewN/AView Earnings Details
7/29/2013Q2 2013($0.18)($0.26)$308.02 million$310.80 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.06)$0.03$307.85 million$328.40 millionViewN/AView Earnings Details
1/29/2013Q4 2012($0.07)($0.35)$318.53 million$334.00 millionViewN/AView Earnings Details
11/1/2012Q312$0.34$0.13$377.14 million$336.00 millionViewN/AView Earnings Details
7/30/2012$0.68$0.46ViewN/AView Earnings Details
4/26/2012$0.57$0.43ViewN/AView Earnings Details
2/2/2012$0.76$0.74ViewN/AView Earnings Details
10/27/2011$0.17$0.70ViewN/AView Earnings Details
7/28/2011($1.00)($0.67)ViewN/AView Earnings Details
5/3/2011($1.09)($0.91)ViewN/AView Earnings Details
2/3/2011($0.93)($0.74)ViewN/AView Earnings Details
10/25/2010Q3 2010($0.91)($0.99)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.83)($0.83)ViewN/AView Earnings Details
4/21/2010Q1 2010($0.78)($0.80)ViewN/AView Earnings Details
2/4/2010Q4 2009($0.85)($0.75)ViewN/AView Earnings Details
10/26/2009Q3 2009($0.80)($0.83)ViewN/AView Earnings Details
8/5/2009Q2 2009($0.80)($0.92)ViewN/AView Earnings Details
4/16/2009Q1 2009($0.84)($0.97)ViewN/AView Earnings Details
2/9/2009Q4 2008($0.92)($0.95)ViewN/AView Earnings Details
10/27/2008Q3 2008($0.91)($0.93)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.62)($0.65)ViewN/AView Earnings Details
4/21/2008Q1 2008($0.63)($0.72)ViewN/AView Earnings Details
2/11/2008Q4 2007($0.69)($0.66)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Vertex Pharmaceuticals (NASDAQ:VRTX) Earnings Estimates

2018 EPS Consensus Estimate: $1.42
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.28$0.30$0.29
Q2 20182$0.24$0.36$0.30
Q3 20182$0.29$0.47$0.38
Q4 20182$0.33$0.57$0.45
(Earnings estimates data provided by Zacks Investment Research)


Vertex Pharmaceuticals (NASDAQ:VRTX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Vertex Pharmaceuticals (NASDAQ VRTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.80%
Institutional Ownership Percentage: 93.19%
Insider Trades by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)
Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals (NASDAQ VRTX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/16/2018Jeffrey ChodakewitzCMOSell1,719$157.28$270,364.3256,143View SEC Filing  
1/16/2018Jeffrey M LeidenCEOSell99,563$156.99$15,630,395.37176,747View SEC Filing  
1/16/2018Stuart A ArbuckleEVPSell2,125$158.28$336,345.0044,077View SEC Filing  
1/11/2018Stuart A ArbuckleEVPSell4,250$159.00$675,750.0046,202View SEC Filing  
1/5/2018Sangeeta N BhatiaDirectorSell10,753$156.00$1,677,468.0014,706View SEC Filing  
1/2/2018Jeffrey ChodakewitzCMOSell3,438$151.80$521,888.4057,862View SEC Filing  
1/2/2018Thomas GraneyCFOSell777$149.95$116,511.15View SEC Filing  
12/27/2017Paul M SilvaSVPSell1,289$152.31$196,327.5917,923View SEC Filing  
12/11/2017Jeffrey M LeidenCEOSell125,000$141.35$17,668,750.00237,407View SEC Filing  
11/15/2017Stuart A ArbuckleEVPSell221$147.29$32,551.09View SEC Filing  
11/6/2017Ian F SmithCOOSell6,405$150.00$960,750.00View SEC Filing  
11/6/2017Stuart A ArbuckleEVPSell4,250$148.17$629,722.5046,202View SEC Filing  
11/3/2017Ian F SmithCOOSell2,155$150.00$323,250.0043,043View SEC Filing  
11/3/2017Jeffrey ChodakewitzCMOSell5,390$144.71$779,986.9056,220View SEC Filing  
11/3/2017Michael PariniEVPSell2,330$149.50$348,335.0031,139View SEC Filing  
11/3/2017Sangeeta N BhatiaDirectorSell7,073$143.05$1,011,792.6511,026View SEC Filing  
10/31/2017Amit SachdevEVPSell40,000$145.05$5,802,000.0089,810View SEC Filing  
10/31/2017Ian F SmithCOOSell75,000$145.06$10,879,500.00114,188View SEC Filing  
10/31/2017Jeffrey ChodakewitzCMOSell60,000$145.05$8,703,000.00113,024View SEC Filing  
10/27/2017Stuart A ArbuckleEVPSell6,290$143.97$905,571.30116,952View SEC Filing  
10/16/2017Ian F SmithCOOSell2,125$155.61$330,671.25118,013View SEC Filing  
10/16/2017Jeffrey ChodakewitzCMOSell1,718$155.19$266,616.42116,142View SEC Filing  
10/12/2017Michael PariniEVPSell2,125$152.93$324,976.25View SEC Filing  
10/2/2017Jeffrey ChodakewitzCMOSell3,437$151.64$521,186.68View SEC Filing  
8/31/2017David AltshulerEVPSell1,796$160.00$287,360.00107,807View SEC Filing  
8/7/2017Ian F SmithCFOSell4,250$155.39$660,407.50120,138View SEC Filing  
8/7/2017Paul M SilvaSVPSell1,289$152.88$197,062.3217,923View SEC Filing  
8/3/2017Jeffrey ChodakewitzCMOSell5,390$154.17$830,976.30116,220View SEC Filing  
8/3/2017Michael PariniEVPSell2,330$155.72$362,827.6031,139View SEC Filing  
8/2/2017Ian F SmithCFOSell2,155$154.17$332,236.35118,043View SEC Filing  
8/2/2017Jeffrey ChodakewitzCMOSell1,796$154.13$276,817.48116,220View SEC Filing  
8/2/2017Paul M SilvaSVPSell1,289$151.80$195,670.2017,923View SEC Filing  
7/31/2017Jeffrey M LeidenCEOSell11,063$152.81$1,690,537.03268,455View SEC Filing  
7/31/2017Paul M SilvaSVPSell860$152.99$131,571.4017,494View SEC Filing  
7/31/2017Stuart A ArbuckleEVPSell2,125$152.99$325,103.75123,242View SEC Filing  
7/21/2017Amit SachdevEVPSell28,625$160.93$4,606,621.25119,335View SEC Filing  
7/21/2017Ian F SmithCFOSell133,750$160.98$21,531,075.00151,738View SEC Filing  
7/21/2017Jeffrey ChodakewitzCMOSell46,733$160.96$7,522,143.68128,814View SEC Filing  
7/21/2017Jeffrey M LeidenCEOSell216,624$160.96$34,867,799.04400,266View SEC Filing  
7/21/2017Paul M SilvaSVPSell43,443$161.07$6,997,364.0126,516View SEC Filing  
7/19/2017Michael PariniEVPSell10,829$161.00$1,743,469.0037,309View SEC Filing  
7/17/2017Jeffrey ChodakewitzCMOSell573$129.85$74,404.05123,084View SEC Filing  
7/3/2017Jeffrey ChodakewitzCMOSell3,438$127.80$439,376.40125,949View SEC Filing  
6/21/2017Jeffrey ChodakewitzCMOSell5,157$132.87$685,210.59127,668View SEC Filing  
6/21/2017Paul M SilvaSVPSell2,577$133.36$343,668.7222,648View SEC Filing  
6/5/2017David AltshulerEVPSell7,500$130.00$975,000.00113,511View SEC Filing  
6/2/2017Jeffrey M LeidenCEOSell147,101$129.50$19,049,579.50312,142View SEC Filing  
6/2/2017Sangeeta N BhatiaDirectorSell1,176$128.44$151,045.445,129View SEC Filing  
6/2/2017Stuart A ArbuckleEVPSell70,969$128.06$9,088,290.14145,061View SEC Filing  
5/2/2017Jeffrey ChodakewitzCMOSell8,979$121.05$1,086,907.95131,490View SEC Filing  
4/28/2017Jeffrey M LeidenCEOSell157,200$119.50$18,785,400.00395,152View SEC Filing  
4/5/2017Jeffrey ChodakewitzCMOSell8,021$114.00$914,394.00130,532View SEC Filing  
4/3/2017Jeffrey ChodakewitzCMOSell2,291$108.85$249,375.35124,802View SEC Filing  
3/29/2017Amit SachdevEVPSell80,500$107.63$8,664,215.00105,054View SEC Filing  
3/29/2017Jeffrey ChodakewitzCMOSell13,750$106.65$1,466,437.50136,261View SEC Filing  
3/29/2017Paul M SilvaSVPSell1,688$106.30$179,434.4021,759View SEC Filing  
1/11/2017Joshua S BogerDirectorSell8,000$82.48$659,840.00276,225View SEC Filing  
1/4/2017Joshua S BogerDirectorSell6,500$77.13$501,345.00274,725View SEC Filing  
12/29/2016Joshua S BogerDirectorSell6,500$74.33$483,145.00274,725View SEC Filing  
12/21/2016Joshua S BogerDirectorSell6,500$74.16$482,040.00274,725View SEC Filing  
12/14/2016Joshua S BogerDirectorSell6,500$77.52$503,880.00274,725View SEC Filing  
11/30/2016Joshua S BogerDirectorSell6,500$83.48$542,620.00274,725View SEC Filing  
11/23/2016Joshua S BogerDirectorSell6,500$86.47$562,055.00274,725View SEC Filing  
11/16/2016Joshua S BogerDirectorSell6,500$91.55$595,075.00274,725View SEC Filing  
11/10/2016Paul M SilvaSVPSell5,062$90.98$460,540.7617,125View SEC Filing  
11/9/2016Joshua S BogerDirectorSell6,500$90.98$591,370.00274,725View SEC Filing  
11/9/2016Stuart A ArbuckleEVPSell1,208$90.00$108,720.00113,358View SEC Filing  
11/2/2016Joshua S BogerDirectorSell6,500$77.75$505,375.00274,725View SEC Filing  
10/26/2016Joshua S BogerDirectorSell6,500$79.26$515,190.00274,725View SEC Filing  
10/19/2016Joshua S BogerDirectorSell6,500$81.84$531,960.00274,725View SEC Filing  
10/12/2016Joshua S BogerDirectorSell6,500$81.14$527,410.00274,725View SEC Filing  
10/5/2016Joshua S BogerDirectorSell6,500$87.44$568,360.00274,725View SEC Filing  
10/3/2016Stuart A ArbuckleEVPSell1,208$86.46$104,443.68114,566View SEC Filing  
9/28/2016Joshua S BogerDirectorSell6,500$88.15$572,975.00274,725View SEC Filing  
9/21/2016Joshua S BogerDirectorSell6,500$90.82$590,330.00274,725View SEC Filing  
9/14/2016Joshua S BogerDirectorSell6,500$92.37$600,405.00274,725View SEC Filing  
9/7/2016Joshua S BogerDirectorSell6,500$95.66$621,790.00274,725View SEC Filing  
8/31/2016Joshua S BogerDirectorSell6,500$94.62$615,030.00274,725View SEC Filing  
8/24/2016Joshua S BogerDirectorSell7,500$100.46$753,450.00274,725View SEC Filing  
8/22/2016Joshua S BogerDirectorSell1,100$100.79$110,869.00268,225View SEC Filing  
8/17/2016Joshua S BogerDirectorSell6,900$99.63$687,447.00274,725View SEC Filing  
8/11/2016Joshua S BogerDirectorSell900$100.19$90,171.00268,225View SEC Filing  
8/10/2016Joshua S BogerDirectorSell7,100$100.24$711,704.00274,725View SEC Filing  
8/3/2016Joshua S BogerDirectorSell47,000$100.66$4,731,020.00274,725View SEC Filing  
7/27/2016Joshua S BogerDirectorSell6,500$95.93$623,545.00274,725View SEC Filing  
7/20/2016Joshua S BogerDirectorSell6,500$90.33$587,145.00274,725View SEC Filing  
7/13/2016Joshua S BogerDirectorSell6,500$88.81$577,265.00274,725View SEC Filing  
7/6/2016Joshua S BogerDirectorSell5,140$88.99$457,408.60273,365View SEC Filing  
6/29/2016Joshua S BogerDirectorSell5,130$84.82$435,126.60273,355View SEC Filing  
6/22/2016Joshua S BogerDirectorSell5,130$86.61$444,309.30273,355View SEC Filing  
6/15/2016Joshua S BogerDirectorSell5,130$91.18$467,753.40273,355View SEC Filing  
6/8/2016Joshua S BogerDirectorSell5,130$94.95$487,093.50273,355View SEC Filing  
6/1/2016Joshua S BogerDirectorSell5,130$93.65$480,424.50268,225View SEC Filing  
5/25/2016Joshua S BogerDirectorSell5,130$89.09$457,031.70270,414View SEC Filing  
5/18/2016Joshua S BogerDirectorSell5,130$81.18$416,453.40270,414View SEC Filing  
5/16/2016Amit SachdevEVPSell117$81.67$9,555.3986,096View SEC Filing  
5/16/2016Ian F SmithCFOSell202$82.06$16,576.12112,999View SEC Filing  
5/11/2016Joshua S BogerDirectorSell5,130$86.50$443,745.00270,414View SEC Filing  
5/9/2016Paul M SilvaSVPSell3,000$87.63$262,890.0015,950View SEC Filing  
5/4/2016Joshua S BogerDirectorSell5,130$81.02$415,632.60270,414View SEC Filing  
4/27/2016Joshua S BogerDirectorSell5,130$83.67$429,227.10270,414View SEC Filing  
4/20/2016Joshua S BogerDirectorSell5,130$84.10$431,433.00270,414View SEC Filing  
4/13/2016Joshua S BogerDirectorSell5,130$84.27$432,305.10270,414View SEC Filing  
4/6/2016Joshua S BogerDirectorSell5,130$89.56$459,442.80270,414View SEC Filing  
3/30/2016Joshua S BogerDirectorSell5,130$78.83$404,397.90270,414View SEC Filing  
3/23/2016Joshua S BogerDirectorSell5,130$81.38$417,479.40270,414View SEC Filing  
3/16/2016Joshua S BogerDirectorSell5,130$79.65$408,604.50270,414View SEC Filing  
3/2/2016Joshua S BogerDirectorSell5,130$91.80$470,934.00274,425View SEC Filing  
2/24/2016Joshua S BogerDirectorSell5,130$85.25$437,332.50274,425View SEC Filing  
2/17/2016Joshua S. BogerDirectorSell5,130$86.93$445,950.90265,284View SEC Filing  
2/10/2016Joshua S. BogerDirectorSell5,130$82.57$423,584.10265,284View SEC Filing  
2/3/2016Ian F. SmithCFOSell12,084$90.84$1,097,710.56112,999View SEC Filing  
2/3/2016Jeffrey M. LeidenCEOSell9,834$90.82$893,123.88261,885View SEC Filing  
2/3/2016Joshua S. BogerDirectorSell5,130$90.81$465,855.30265,284View SEC Filing  
2/3/2016Paul M. SilvaSVPSell5,062$90.82$459,730.8416,750View SEC Filing  
2/3/2016Stuart A. ArbuckleEVPSell6,042$90.82$548,734.44115,721View SEC Filing  
2/2/2016Jeffrey ChodakewitzCMOSell2,375$91.38$217,027.50112,603View SEC Filing  
1/27/2016Joshua S. BogerDirectorSell11,200$93.22$1,044,064.00265,284View SEC Filing  
1/20/2016Joshua S. BogerDirectorSell10,400$93.69$974,376.00265,284View SEC Filing  
1/13/2016Joshua S. BogerDirectorSell10,400$98.41$1,023,464.00265,284View SEC Filing  
1/6/2016Joshua S. BogerDirectorSell10,400$121.96$1,268,384.00265,284View SEC Filing  
1/4/2016Yuchun LeeDirectorSell1,125$122.21$137,486.251,041View SEC Filing  
12/30/2015Joshua S. BogerDirectorSell10,400$127.15$1,322,360.00265,284View SEC Filing  
12/21/2015Joshua S. BogerDirectorSell10,400$119.26$1,240,304.00265,284View SEC Filing  
12/9/2015Joshua S. BogerDirectorSell10,400$120.80$1,256,320.00265,284View SEC Filing  
12/4/2015Stuart A. ArbuckleEVPSell4,531$123.98$561,753.38104,464View SEC Filing  
12/2/2015Joshua S. BogerDirectorSell10,400$130.91$1,361,464.00265,284View SEC Filing  
12/1/2015David AltshulerEVPSell5,000$131.00$655,000.0075,000View SEC Filing  
12/1/2015Yuchun LeeDirectorSell1,125$129.65$145,856.25833View SEC Filing  
11/23/2015Joshua S. BogerDirectorSell10,400$132.18$1,374,672.00265,284View SEC Filing  
11/11/2015Joshua S. BogerDirectorSell10,400$118.59$1,233,336.00345,284View SEC Filing  
11/4/2015Joshua S. BogerDirectorSell10,400$124.23$1,291,992.00345,284View SEC Filing  
11/2/2015Yuchun LeeDirectorSell1,125$126.19$141,963.75625View SEC Filing  
10/28/2015Joshua S. BogerDirectorSell10,400$119.01$1,237,704.00345,284View SEC Filing  
10/21/2015Joshua S. BogerDirectorSell10,400$108.82$1,131,728.00345,284View SEC Filing  
10/14/2015Joshua S. BogerDirectorSell10,400$112.62$1,171,248.00345,284View SEC Filing  
10/7/2015Joshua S. BogerDirectorSell10,400$109.61$1,139,944.00345,284View SEC Filing  
10/2/2015Elaine UllianDirectorSell20,000$110.00$2,200,000.005,265View SEC Filing  
10/1/2015Stuart A. ArbuckleEVPSell12,417$104.71$1,300,184.07115,098View SEC Filing  
10/1/2015Yuchun LeeDirectorSell1,125$104.64$117,720.00416View SEC Filing  
9/30/2015Joshua S. BogerDirectorSell10,400$103.14$1,072,656.00345,284View SEC Filing  
9/23/2015Joshua S. BogerDirectorSell10,400$111.89$1,163,656.00345,284View SEC Filing  
9/16/2015Joshua S. BogerDirectorSell10,400$133.24$1,385,696.00345,284View SEC Filing  
9/9/2015Joshua S. BogerDirectorSell10,400$131.41$1,366,664.00345,284View SEC Filing  
9/4/2015Stuart A. ArbuckleEVPSell9,063$125.77$1,139,853.51127,515View SEC Filing  
9/2/2015Joshua S. BogerDirectorSell10,400$125.85$1,308,840.00345,284View SEC Filing  
9/1/2015Yuchun LeeDirectorSell1,125$125.40$141,075.00208View SEC Filing  
8/26/2015Joshua S. BogerDirectorSell10,400$124.71$1,296,984.00345,284View SEC Filing  
8/19/2015Joshua S. BogerDirectorSell10,400$139.93$1,455,272.00345,284View SEC Filing  
8/12/2015Joshua S BogerDirectorSell10,400$135.83$1,412,632.00View SEC Filing  
7/22/2015Joshua S BogerDirectorSell10,400$130.92$1,361,568.00View SEC Filing  
7/15/2015Joshua S BogerDirectorSell12,200$133.98$1,634,556.00View SEC Filing  
7/13/2015Paul M SilvaSVPSell1,125$123.79$139,263.75View SEC Filing  
7/8/2015Joshua S BogerDirectorSell11,700$122.74$1,436,058.00View SEC Filing  
7/2/2015Jeffrey ChodakewitzCMOSell2,291$129.36$296,363.76View SEC Filing  
7/1/2015Joshua S BogerDirectorSell11,700$125.60$1,469,520.00View SEC Filing  
6/24/2015Joshua S BogerDirectorSell11,700$130.41$1,525,797.00View SEC Filing  
6/17/2015Joshua S BogerDirectorSell11,700$123.90$1,449,630.00View SEC Filing  
6/10/2015Joshua S BogerDirectorSell11,700$125.02$1,462,734.00View SEC Filing  
5/20/2015Joshua S BogerDirectorSell11,700$126.73$1,482,741.00View SEC Filing  
5/6/2015Joshua S BogerDirectorSell11,700$122.79$1,436,643.00View SEC Filing  
5/5/2015Paul M SilvaSVPSell4,101$123.68$507,211.68View SEC Filing  
4/29/2015Joshua S BogerDirectorSell11,700$124.59$1,457,703.00View SEC Filing  
4/27/2015Paul M SilvaSVPSell1,125$129.74$145,957.50View SEC Filing  
4/27/2015Stuart A ArbuckleEVPSell61,480$129.36$7,953,052.80View SEC Filing  
4/27/2015Terrence C KearneyDirectorSell68,125$129.11$8,795,618.75View SEC Filing  
4/22/2015Joshua S BogerDirectorSell11,700$132.46$1,549,782.00View SEC Filing  
4/15/2015Joshua S BogerDirectorSell11,700$129.25$1,512,225.00View SEC Filing  
4/13/2015Paul M SilvaSVPSell1,125$128.60$144,675.00View SEC Filing  
4/8/2015Joshua S BogerDirectorSell11,700$123.26$1,442,142.00View SEC Filing  
4/6/2015Margaret G McglynnDirectorSell12,500$118.36$1,479,500.00View SEC Filing  
4/2/2015Jeffrey ChodakewitzCMOSell2,291$115.50$264,610.50View SEC Filing  
4/1/2015Joshua S BogerDirectorSell11,700$115.87$1,355,679.00View SEC Filing  
3/25/2015Joshua S BogerDirectorSell11,700$120.76$1,412,892.00View SEC Filing  
3/23/2015Amit SachdevEVPSell17,083$132.28$2,259,739.24View SEC Filing  
3/23/2015Ian F SmithCFOSell6,042$125.67$759,298.14View SEC Filing  
3/23/2015Paul M SilvaSVPSell2,250$125.65$282,712.50View SEC Filing  
3/18/2015Amit SachdevEVPSell12,000$130.00$1,560,000.00View SEC Filing  
2/5/2015Paul M SilvaSVPSell1,688$109.75$185,258.00View SEC Filing  
2/4/2015Joshua S BogerDirectorSell5,700$108.81$620,217.00View SEC Filing  
2/3/2015Paul M SilvaSVPSell2,063$108.89$224,640.07View SEC Filing  
2/2/2015Jeffrey ChodakewitzCMOSell1,188$109.60$130,204.80View SEC Filing  
1/28/2015Joshua S BogerDirectorSell10,688$122.78$1,312,272.64View SEC Filing  
1/26/2015Paul M SilvaSVPSell1,125$125.62$141,322.50View SEC Filing  
1/21/2015Joshua S BogerDirectorSell10,500$125.08$1,313,340.00View SEC Filing  
1/14/2015Joshua S BogerDirectorSell10,500$120.16$1,261,680.00View SEC Filing  
1/9/2015Amit SachdevEVPSell12,000$125.00$1,500,000.00View SEC Filing  
1/9/2015Bruce I SachsDirectorSell9,861$125.04$1,233,019.44View SEC Filing  
1/7/2015Joshua S BogerDirectorSell10,500$119.32$1,252,860.00View SEC Filing  
1/2/2015Jeffrey ChodakewitzCMOSell2,291$122.54$280,739.14View SEC Filing  
12/22/2014Joshua S BogerDirectorSell10,500$117.65$1,235,325.00View SEC Filing  
12/17/2014Joshua S BogerDirectorSell10,500$110.66$1,161,930.00View SEC Filing  
12/15/2014Jeffrey M LeidenCEOSell50,017$114.97$5,750,454.49View SEC Filing  
12/12/2014Paul M SilvaSVPSell2,813$120.08$337,785.04View SEC Filing  
11/28/2014Amit SachdevEVPSell12,000$120.00$1,440,000.00View SEC Filing  
11/28/2014Bruce I SachsDirectorSell10,000$120.03$1,200,300.00View SEC Filing  
11/28/2014Paul M SilvaSVPSell8,164$119.85$978,455.40View SEC Filing  
11/26/2014Joshua S BogerDirectorSell10,500$114.54$1,202,670.00View SEC Filing  
11/6/2014Bruce I SachsDirectorSell9,900$115.21$1,140,579.00View SEC Filing  
11/5/2014Bruce I SachsDirectorSell30,100$112.62$3,389,862.00View SEC Filing  
11/3/2014Joshua S BogerDirectorSell127,411$112.20$14,295,514.20View SEC Filing  
10/29/2014Joshua S BogerDirectorSell10,500$109.44$1,149,120.00View SEC Filing  
10/28/2014Amit SachdevEVPSell12,000$115.00$1,380,000.00View SEC Filing  
10/28/2014David AltshulerDirectorSell2,000$114.75$229,500.00View SEC Filing  
10/28/2014Jeffrey ChodakewitzCMOSell3,438$115.00$395,370.00View SEC Filing  
10/27/2014Paul M SilvaSVPSell1,125$110.03$123,783.75View SEC Filing  
10/13/2014Paul M SilvaSVPSell1,125$107.89$121,376.25View SEC Filing  
10/7/2014Jeffrey ChodakewitzCMOSell3,436$104.26$358,237.36View SEC Filing  
10/6/2014David AltshulerDirectorSell1,405$109.75$154,198.75View SEC Filing  
10/1/2014Elaine UllianDirectorSell5,000$107.74$538,700.00View SEC Filing  
10/1/2014Stuart A ArbuckleEVPSell12,417$107.71$1,337,435.07View SEC Filing  
9/30/2014Amit SachdevSVPSell86,000$112.68$9,690,480.00View SEC Filing  
9/30/2014Ian F SmithCFOSell108,026$112.68$12,172,369.68View SEC Filing  
9/30/2014Jeffrey M LeidenCEOSell200,000$112.69$22,538,000.00View SEC Filing  
9/30/2014Kenneth L HortonEVPSell36,000$112.69$4,056,840.00View SEC Filing  
9/29/2014David AltshulerDirectorSell2,500$114.75$286,875.00View SEC Filing  
9/24/2014Joshua S BogerDirectorSell5,200$109.21$567,892.00View SEC Filing  
9/19/2014David AltshulerDirectorSell5,000$102.25$511,250.00View SEC Filing  
9/19/2014Paul M SilvaSVPSell25,408$99.85$2,536,988.80View SEC Filing  
9/19/2014Stuart A ArbuckleEVPSell55,521$100.00$5,552,100.00View SEC Filing  
9/17/2014Joshua S BogerDirectorSell5,200$93.62$486,824.00View SEC Filing  
9/10/2014Joshua S BogerDirectorSell5,200$94.42$490,984.00View SEC Filing  
9/5/2014David AltshulerDirectorSell2,500$94.75$236,875.00View SEC Filing  
9/3/2014Joshua S BogerDirectorSell5,200$92.79$482,508.00View SEC Filing  
8/27/2014Joshua S BogerDirectorSell5,200$93.31$485,212.00View SEC Filing  
8/20/2014Joshua S BogerDirectorSell5,200$91.51$475,852.00View SEC Filing  
8/13/2014Joshua S BogerDirectorSell5,200$88.00$457,600.00View SEC Filing  
8/6/2014Joshua S BogerDirectorSell5,200$86.54$450,008.00View SEC Filing  
7/31/2014David AltshulerDirectorSell5,000$89.59$447,950.00View SEC Filing  
7/31/2014Paul M SilvaSVPSell2,027$88.97$180,342.19View SEC Filing  
7/30/2014Joshua S BogerDirectorSell5,200$92.17$479,284.00View SEC Filing  
7/15/2014Wayne Joseph RileyDirectorSell4,800$96.65$463,920.00View SEC Filing  
7/1/2014Elaine UllianDirectorSell5,000$95.21$476,050.00View SEC Filing  
7/1/2014Kenneth L HortonEVPSell30,134$95.22$2,869,359.48View SEC Filing  
6/24/2014Megan E PaceSVPSell12,734$98.03$1,248,314.02View SEC Filing  
6/24/2014Wayne Joseph RileyDirectorSell15,000$98.03$1,470,450.00View SEC Filing  
6/16/2014Peter MuellerEVPSell7,500$68.31$512,325.00View SEC Filing  
6/9/2014Elaine UllianDirectorSell2,500$75.00$187,500.00View SEC Filing  
5/14/2014Peter MuellerEVPSell7,500$67.45$505,875.00143,517View SEC Filing  
5/2/2014Megan PaceSVPSell1,000$67.62$67,620.0023,350View SEC Filing  
4/15/2014Peter MuellerEVPSell7,500$61.63$462,225.00158,750View SEC Filing  
4/9/2014Elaine UllianDirectorSell2,500$70.00$175,000.005,265View SEC Filing  
3/21/2014Bruce SachsDirectorSell8,700$74.59$648,933.0021,210View SEC Filing  
3/17/2014Peter MuellerEVPSell7,500$78.29$587,175.00158,750View SEC Filing  
2/7/2014Jeffrey LeidenCEOSell35,944$80.00$2,875,520.00211,481View SEC Filing  
1/22/2014Bruce SachsDirectorSell8,300$84.47$701,101.0038,210View SEC Filing  
1/21/2014Megan PaceSVPSell1,250$85.00$106,250.0010,100View SEC Filing  
1/16/2014Jeffrey LeidenCEOSell45,000$80.00$3,600,000.00182,925View SEC Filing  
1/15/2014Peter MuellerEVPSell7,500$78.67$590,025.00141,500View SEC Filing  
12/23/2013Bruce SachsDirectorSell8,300$73.02$606,066.0046,510View SEC Filing  
12/16/2013Peter MuellerEVPSell7,500$64.69$485,175.00141,500View SEC Filing  
12/12/2013Jeffrey LeidenCEOSell9,834$65.48$643,930.32182,925View SEC Filing  
12/12/2013Kenneth HortonEVPSell4,532$65.46$296,664.7216,624View SEC Filing  
12/12/2013Megan PaceSVPSell5,083$65.48$332,834.8412,188View SEC Filing  
12/4/2013Joshua BogerDirectorSell1,400$67.48$94,472.00338,895View SEC Filing  
11/25/2013Joshua BogerDirectorSell1,400$66.89$93,646.00338,895View SEC Filing  
11/20/2013Bruce SachsDirectorSell8,300$65.28$541,824.0054,810View SEC Filing  
11/19/2013Joshua BogerDirectorSell1,400$62.31$87,234.00338,895View SEC Filing  
11/5/2013Joshua BogerDirectorSell1,400$65.64$91,896.00338,895View SEC Filing  
10/29/2013Joshua S BogerDirectorSell1,400$75.42$105,588.00View SEC Filing  
10/29/2013Thomas ConnollySVPSell1,688$75.04$126,667.52View SEC Filing  
10/24/2013Bruce I SachsDirectorSell8,300$77.06$639,598.00View SEC Filing  
10/23/2013Joshua S BogerDirectorSell1,400$76.77$107,478.00View SEC Filing  
10/16/2013Joshua S BogerDirectorSell1,400$75.41$105,574.00View SEC Filing  
10/15/2013Peter MuellerEVPSell7,500$73.25$549,375.00View SEC Filing  
10/14/2013Paul SilvaSVPSell1,593$71.87$114,488.9111,750View SEC Filing  
10/9/2013Joshua BogerDirectorSell1,400$72.35$101,290.00338,895View SEC Filing  
9/25/2013Joshua BogerDirectorSell1,400$74.72$104,608.00338,895View SEC Filing  
9/18/2013Joshua BogerDirectorSell1,400$77.43$108,402.00338,895View SEC Filing  
9/16/2013Peter MuellerEVPSell7,500$77.22$579,150.00144,400View SEC Filing  
9/11/2013Joshua BogerDirectorSell1,400$79.61$111,454.00338,895View SEC Filing  
9/4/2013Joshua BogerDirectorSell1,400$75.45$105,630.00338,895View SEC Filing  
8/29/2013Bruce SachsDirectorSell8,300$77.19$640,677.0079,710View SEC Filing  
8/28/2013Joshua BogerDirectorSell1,400$76.24$106,736.00338,895View SEC Filing  
8/21/2013Joshua BogerDirectorSell1,400$76.96$107,744.00338,895View SEC Filing  
8/15/2013Peter MuellerEVPSell7,500$77.41$580,575.00144,400View SEC Filing  
8/14/2013Joshua BogerDirectorSell1,400$77.18$108,052.00338,895View SEC Filing  
8/7/2013Joshua BogerDirectorSell1,400$77.84$108,976.00338,895View SEC Filing  
8/5/2013Paul SilvaSVPSell3,001$78.90$236,778.9011,750View SEC Filing  
7/31/2013Joshua S BogerDirectorSell1,400$80.89$113,246.00View SEC Filing  
7/29/2013Wayne Joseph RileyDirectorSell9,800$80.09$784,882.00View SEC Filing  
7/25/2013Paul M SilvaSVPSell1,125$86.49$97,301.25View SEC Filing  
7/24/2013Bruce I SachsDirectorSell8,300$85.50$709,650.00View SEC Filing  
7/19/2013Amit SachdevSVPSell22,250$88.69$1,973,352.50View SEC Filing  
7/18/2013Joshua S BogerDirectorSell1,400$86.12$120,568.00View SEC Filing  
7/16/2013Paul M SilvaSVPSell2,063$86.25$177,933.75View SEC Filing  
7/15/2013Christiana StamoulisSVPSell1,125$86.35$97,143.75View SEC Filing  
7/15/2013Peter MuellerEVPSell7,500$86.34$647,550.00View SEC Filing  
7/12/2013Megan E PaceSVPSell10,678$85.00$907,630.00View SEC Filing  
7/11/2013Joshua S BogerDirectorSell1,400$83.83$117,362.00View SEC Filing  
7/8/2013Kenneth L HortonEVPSell1,813$80.72$146,345.36View SEC Filing  
7/8/2013Megan E PaceSVPSell28,703$80.89$2,321,785.67View SEC Filing  
7/5/2013Christiana StamoulisSVPSell4,687$81.21$380,631.27View SEC Filing  
7/3/2013Joshua S BogerDirectorSell1,400$80.20$112,280.00View SEC Filing  
7/2/2013Peter MuellerEVPSell122,300$79.80$9,759,540.00View SEC Filing  
6/26/2013Joshua S BogerDirectorSell1,400$78.59$110,026.00View SEC Filing  
6/21/2013Bruce I SachsDirectorSell8,300$75.93$630,219.00View SEC Filing  
6/19/2013Joshua S BogerDirectorSell1,400$79.11$110,754.00View SEC Filing  
6/12/2013Joshua S BogerDirectorSell1,400$81.19$113,666.00View SEC Filing  
6/5/2013Joshua S BogerDirectorSell1,400$77.15$108,010.00View SEC Filing  
5/30/2013Joshua S BogerDirectorSell1,400$82.47$115,458.00View SEC Filing  
5/22/2013Joshua S BogerDirectorSell1,400$79.72$111,608.00View SEC Filing  
5/15/2013Joshua S BogerDirectorSell1,400$79.36$111,104.00View SEC Filing  
5/14/2013Bruce I SachsDirectorSell60,000$81.15$4,869,000.00View SEC Filing  
12/26/2012Joshua S BogerDirectorSell4,000$41.86$167,440.00View SEC Filing  
11/7/2012Margaret G McglynnDirectorBuy1,000$45.50$45,500.00View SEC Filing  
10/8/2012Ian F SmithCFOSell44,787$60.00$2,687,220.00View SEC Filing  
10/3/2012Joshua S BogerDirectorSell4,000$57.74$230,960.00View SEC Filing  
9/5/2012Joshua S BogerDirectorSell4,000$54.70$218,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Vertex Pharmaceuticals (NASDAQ VRTX) News Headlines

Vertex Pharmaceuticals (VRTX) Cut to "Hold" at Zacks Investment ResearchVertex Pharmaceuticals (VRTX) Cut to "Hold" at Zacks Investment Research - January 21 at 8:46 AM
Which Biotech Stocks Could Surprise To The Upside On Earnings?Which Biotech Stocks Could Surprise To The Upside On Earnings? - January 19 at 4:41 PM
Vertex Pharmaceuticals: Set To Wow In 18 - Seeking AlphaVertex Pharmaceuticals: Set To Wow In '18 - Seeking Alpha - January 19 at 12:13 PM
FY2017 Earnings Forecast for Vertex Pharmaceuticals Incorporated Issued By Leerink Swann (VRTX)FY2017 Earnings Forecast for Vertex Pharmaceuticals Incorporated Issued By Leerink Swann (VRTX) - January 19 at 10:08 AM
RPG, VRTX, CNC, PHM: Large Outflows Detected at ETFRPG, VRTX, CNC, PHM: Large Outflows Detected at ETF - January 18 at 3:48 PM
Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $15.6 million of SharesVertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $15.6 million of Shares - January 18 at 11:43 AM
Vertex Pharmaceuticals Incorporated (VRTX) Expected to Announce Quarterly Sales of $593.83 MillionVertex Pharmaceuticals Incorporated (VRTX) Expected to Announce Quarterly Sales of $593.83 Million - January 18 at 8:14 AM
Insider Selling: Vertex Pharmaceuticals Incorporated (VRTX) CMO Sells 1,719 Shares of StockInsider Selling: Vertex Pharmaceuticals Incorporated (VRTX) CMO Sells 1,719 Shares of Stock - January 17 at 7:04 PM
Vertex Pharmaceuticals Incorporated (VRTX) EVP Sells $336,345.00 in StockVertex Pharmaceuticals Incorporated (VRTX) EVP Sells $336,345.00 in Stock - January 17 at 7:04 PM
Jeffrey M. Leiden Sells 99,563 Shares of Vertex Pharmaceuticals Incorporated (VRTX) StockJeffrey M. Leiden Sells 99,563 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock - January 17 at 6:28 PM
3 Biotech Stocks Start Healthy in '18: Will the Rally Last?3 Biotech Stocks Start Healthy in '18: Will the Rally Last? - January 16 at 4:18 PM
Can Vertex Pharmaceuticals Report Solid 2017 Net Profit Margins?Can Vertex Pharmaceuticals Report Solid 2017 Net Profit Margins? - January 16 at 4:18 PM
Insider Selling: Vertex Pharmaceuticals Incorporated (VRTX) EVP Sells 4,250 Shares of StockInsider Selling: Vertex Pharmaceuticals Incorporated (VRTX) EVP Sells 4,250 Shares of Stock - January 12 at 6:26 PM
Vertexs Cystic Fibrosis Drug Given The Okay For Pediatric Use In EuropeVertex's Cystic Fibrosis Drug Given The Okay For Pediatric Use In Europe - January 12 at 10:37 AM
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and VertexThe Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex - January 12 at 10:37 AM
Vertexs Cystic Fibrosis Drug Okd for Pediatric Use in EUVertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EU - January 11 at 11:03 AM
Analysts’ Recommendations for Bioverativ in January 2018Analysts’ Recommendations for Bioverativ in January 2018 - January 10 at 4:20 PM
Vertex Pharma Granted Extension Of Marketing Authorization For ORKAMBI In EuropeVertex Pharma Granted Extension Of Marketing Authorization For ORKAMBI In Europe - January 10 at 10:41 AM
What Should We Expect From Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) Earnings Over The Next Few Years?What Should We Expect From Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) Earnings Over The Next Few Years? - January 10 at 10:41 AM
Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del MutationVertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation - January 10 at 10:41 AM
Vertex Pharmaceuticals Incorporated (VRTX) Director Sangeeta N. Bhatia Sells 10,753 SharesVertex Pharmaceuticals Incorporated (VRTX) Director Sangeeta N. Bhatia Sells 10,753 Shares - January 9 at 6:50 PM
Vertex Pharmaceuticals (VRTX) Buy Rating Reiterated at JPMorgan Chase & Co.Vertex Pharmaceuticals' (VRTX) Buy Rating Reiterated at JPMorgan Chase & Co. - January 9 at 11:22 AM
Critical Contrast: Vertex Pharmaceuticals (VRTX) versus Achillion Pharmaceuticals (ACHN)Critical Contrast: Vertex Pharmaceuticals (VRTX) versus Achillion Pharmaceuticals (ACHN) - January 9 at 5:10 AM
Amgens (AMGN) Xgeva Gets FDA Approval for Multiple MyelomaAmgen's (AMGN) Xgeva Gets FDA Approval for Multiple Myeloma - January 8 at 4:25 PM
Vertex Pharmas Earnings PreviewVertex Pharma's Earnings Preview - January 8 at 4:25 PM
Amgen's (AMGN) Xgeva Gets FDA Approval for Multiple MyelomaAmgen's (AMGN) Xgeva Gets FDA Approval for Multiple Myeloma - January 8 at 4:25 PM
Vertex Pharmaceuticals Incorporated (VRTX) Given Average Rating of "Buy" by BrokeragesVertex Pharmaceuticals Incorporated (VRTX) Given Average Rating of "Buy" by Brokerages - January 8 at 8:00 AM
Vertex Pharmaceuticals Incorporated (VRTX) Forecasted to Earn FY2018 Earnings of $2.37 Per ShareVertex Pharmaceuticals Incorporated (VRTX) Forecasted to Earn FY2018 Earnings of $2.37 Per Share - January 8 at 7:38 AM
Vertex Pharmaceuticals (VRTX) Upgraded to Buy at Bank of AmericaVertex Pharmaceuticals (VRTX) Upgraded to Buy at Bank of America - January 6 at 10:28 PM
Here's What Pushed Crispr Therapeutics AG Up 23.6% in DecemberHere's What Pushed Crispr Therapeutics AG Up 23.6% in December - January 4 at 4:20 PM
Vertex Pharmaceuticals (VRTX) PT Raised to $190.00Vertex Pharmaceuticals (VRTX) PT Raised to $190.00 - January 4 at 9:48 AM
Thomas Graney Sells 777 Shares of Vertex Pharmaceuticals Incorporated (VRTX) StockThomas Graney Sells 777 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock - January 3 at 7:28 PM
Jeffrey Chodakewitz Sells 3,438 Shares of Vertex Pharmaceuticals Incorporated (VRTX) StockJeffrey Chodakewitz Sells 3,438 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock - January 3 at 7:02 PM
Will These 2 Large-Cap Biotechs Be on Investor Radar in 18?Will These 2 Large-Cap Biotechs Be on Investor Radar in '18? - January 3 at 4:22 PM
Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth-Quarter and Full-Year 2017 Financial ResultsVertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth-Quarter and Full-Year 2017 Financial Results - January 3 at 4:22 PM
Will These 2 Large-Cap Biotechs Be on Investor Radar in '18?Will These 2 Large-Cap Biotechs Be on Investor Radar in '18? - January 3 at 9:51 AM
Vertex Pharmaceuticals Incorporated (VRTX) Expected to Post Quarterly Sales of $593.83 MillionVertex Pharmaceuticals Incorporated (VRTX) Expected to Post Quarterly Sales of $593.83 Million - January 1 at 8:52 AM
 Analysts Expect Vertex Pharmaceuticals Incorporated (VRTX) Will Announce Earnings of $0.57 Per Share Analysts Expect Vertex Pharmaceuticals Incorporated (VRTX) Will Announce Earnings of $0.57 Per Share - December 30 at 3:14 PM
Vertex Pharmaceuticals Incorporated (VRTX) SVP Sells $196,327.59 in StockVertex Pharmaceuticals Incorporated (VRTX) SVP Sells $196,327.59 in Stock - December 28 at 6:58 PM
Vertex Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VRTX) : December 26, 2017Vertex Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VRTX) : December 26, 2017 - December 26 at 8:04 PM
Is It Time To Sell Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Based Off Its PE Ratio?Is It Time To Sell Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Based Off Its PE Ratio? - December 26 at 10:48 AM
Contrasting Vertex Pharmaceuticals (VRTX) and Its RivalsContrasting Vertex Pharmaceuticals (VRTX) and Its Rivals - December 24 at 3:22 AM
Q&A: Vertex Chief Talks About Company's 'Transformational Year'Q&A: Vertex Chief Talks About Company's 'Transformational Year' - December 22 at 6:23 PM
Vertex Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VRTX-US : December 22, 2017Vertex Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VRTX-US : December 22, 2017 - December 22 at 10:51 AM
Comparing Vertex Pharmaceuticals (VRTX) and Its CompetitorsComparing Vertex Pharmaceuticals (VRTX) and Its Competitors - December 21 at 11:54 PM
$593.83 Million in Sales Expected for Vertex Pharmaceuticals Incorporated (VRTX) This Quarter$593.83 Million in Sales Expected for Vertex Pharmaceuticals Incorporated (VRTX) This Quarter - December 15 at 6:44 AM
Vertex Pharmaceuticals Incorporated (VRTX) Receives Average Recommendation of "Buy" from BrokeragesVertex Pharmaceuticals Incorporated (VRTX) Receives Average Recommendation of "Buy" from Brokerages - December 14 at 7:44 AM
Analyzing Vertex Pharmaceuticals (VRTX) and The CompetitionAnalyzing Vertex Pharmaceuticals (VRTX) and The Competition - December 14 at 1:18 AM
Vertex Pharmaceuticals Could Be Bought Out for $205 in 2018: Deutsche BankVertex Pharmaceuticals Could Be Bought Out for $205 in 2018: Deutsche Bank - December 13 at 4:29 PM
What Investors Should Know About Vertex Pharmaceuticals Incorporated’s (undefined:VRTX) Financial StrengthWhat Investors Should Know About Vertex Pharmaceuticals Incorporated’s (undefined:VRTX) Financial Strength - December 13 at 4:29 PM

SEC Filings

Vertex Pharmaceuticals (NASDAQ:VRTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Vertex Pharmaceuticals (NASDAQ:VRTX) Income Statement, Balance Sheet and Cash Flow Statement


Vertex Pharmaceuticals (NASDAQ VRTX) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.